Feature | September 06, 2007

Winning Combinations - Hybrids Make Imaging a One-Stop Shop

Hybrids such as GE's Discovery VCT marry the high-speed, high-resolution capabilities of CT with the metabolic and physiologic capabilities of PET.

The continued merging of imaging modalities such as PET/CT, SPECT/CT and MR-PET enable clinicians to better integrate the benefits of complementary modalities. The benefits of these hybrids include faster acquisition times with increased performance in resolution and sensitivity. As these combined modalities enhance imaging for cardiology and oncology, clinicians are able to more accurately diagnosis disease, leading to better patient care and, in the long run, a reduced financial burden on healthcare.
According to Hadi Mougarrej, general manager of Molecular Imaging at GE Healthcare, “[Hybrids] have a clear benefit as one-stop shops in cardiac imaging.”
A key advantage of acquiring complete functional and anatomical data in one scan is that it avoids problems with repositioning a patient and co-registering in the case of acquiring both images separately. This makes it possible for less experienced doctors to achieve the same diagnostic accuracy as highly trained specialists.
“The key is being able to get all your information in a single visit,” said Jay Mazelsky, senior vice president and general manager of Nuclear Medicine at Philips Medical Systems.
“With SPECT/CT you can get comprehensive cardiac imaging in a single episode of care so you could do a true cardiac work-up by having both modalities, resulting in greater diagnostic confidence. Each modality has a best-in-class characteristic, so CT gives you the anatomical localization, while SPECT gives you some of the diagnostic confidence around metabolic function.”
According to Wm. Guy Weigold, M.D., director of Cardiac CT, Div. of Cardiovascular Disease at Washington Hospital Center (D.C.), hybrid imagers offer optimal viewing of the coronary vessels, as they are “rather torturous and complicated in the way they are laid out around the heart.”
“PET/CT is a great way to obtain cardiac functional data from the PET scan and then detailed anatomic information about the heart and the coronary arteries from the CT angiographic data,” he said.
MR-PET offers new insight into neurological disorders
While it is still undergoing research, MR/PET presents a tremendous leap forward in imaging by bringing the exceptional soft tissue contrast and high specificity of MR together with PET’s excellent sensitivity in assessing physiological and metabolic state.
“MR does soft tissue content as well as simultaneous data collection. When imaging a patient, that patient’s condition could change five minutes or even five seconds later. Being able to do PET and MR at exactly the same time can be an advantage,” said Mazelsky.
Researchers expect that MR-PET will open new doors in understanding the pathologies and progression of various neurological disorders like Alzheimer’s, Parkinson’s, epilepsy, depression and schizophrenia.
Cancer types identified and targeted
Nuclear medicine has traditionally focused on radiopharmaceuticals trapped in organ structures and the presence of disease hallmarked by the absence of activity. Exams are then followed with additional procedures, such as a biopsy, to determine the particular disease.
According to Mazelsky, molecular imaging with SPECT/CT offers a different view on traditional SPECT imaging, as newly developed SPECT tracers are target-specific, attracted only to the tissues they’ve been designed to find.
“With agents now entering the market you can actually diagnose a specific type of cancer such as prostate or bladder cancer as opposed to just cancer,” he said.
With MR/PET, clinicians may gain a more sound determination of both cognitive impairment and atrophy of diseases such as Alzheimer’s, as well as the ability to utilize neurological biomarkers. Similarly, MR/PET may allow physicians to study which brain tissues might be salvageable after a stroke.
“Ultimately, [MR/PET] will enable early treatment and highly personalized therapies,” said Lothar Spies, M.D., head of the Digital Imaging Department at Philips Research.
One stop means time and money saved
Hybrid modalities may also offer financial savings for both a hospital and a patient, as smaller numbers of staff will be needed for diagnosis.
“With hybrids you can make a diagnosis within a single episode,” said Mazelsky. “Instead of going to a nuclear medicine department and then to the department of radiology.”
According to Mazelsky, both Medicare and private payers may benefit financially from a hybrid, as some insurance will not reimburse for a second independent exam.
“The economic savings for [hybrids] really comes down to being able to get a diagnosis much quicker, without having to swim around looking for different possible causes of a patient’s condition,” said Mazelsky.

Related Content

PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior

Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior. Image courtesy of Christian Lohrmann, Jason Lewis, Wolfgang Weber, Memorial Sloan Kettering Cancer Center; MabVax Therapeutics

News | PET-CT | June 14, 2017
Pancreatic cancer is associated with bleak five-year survival rates and limited treatment options, but new research is...
PET/CT
News | PET-CT | June 12, 2017
Philips announced that it will be showcasing molecular imaging solutions highlighting Philips’ commitment to innovation...
News | PET-CT | June 12, 2017
Siemens Healthineers has announced that the Food and Drug Administration (FDA) has cleared Biograph Horizon Flow...
advanced visualization
News | Molecular Imaging | June 09, 2017
The Food and Drug Administration (FDA) has cleared syngo.via VB20 for Molecular Imaging (MI) from Siemens Healthineers...
Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients

Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients.

News | PET-CT | June 09, 2017
Oncologists have access to advanced imaging technologies for excellent cancer patient care with the new Celesteion...
Overlay Init